Study of a new VWF treatment for von Willebrand disease in China
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This Phase 3 trial tests an recombinant version of the von Willebrand factor (rVWF) for people with severe von Willebrand disease (VWD) living in China. It aims to see if the drug can safely control bleeding and help those who need regular clotting factor treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with severe VWD confirmed by a doctor.
- You must be 18 years or older.
- You must be of Chinese ethnicity and living in China, Taiwan, Hong Kong, or Macao.
- You must have had at least 3 bleeding episodes in the past year that needed clotting factor treatment.
- Women who could become pregnant must have a negative pregnancy test and use birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests vonicog alfa (an rVWF treatment) to prevent and control bleeding in children with severe von Willebrand disease (vWD). You may be able to join if your child has severe vWD and has been on prior clotting factor treatment with ongoing bleeding despite that care.
This study is testing a new treatment for people with certain types of Von Willebrand disease (Type 1 or 2A) who have frequent bleeding problems. It aims to see if the treatment can help reduce these bleeding episodes.
This trial tests a new drug called VGA039 that is injected under the skin to prevent bleeding episodes in people with von Willebrand disease. It is for those who bleed frequently and are not currently using regular preventive treatments.
This study tests whether SR604, a new injection given under the skin, can reduce bleeding episodes in people with von Willebrand disease (a condition where blood doesn't clot properly). The trial will measure how well it works, how safe it is, and how your body processes it.
This study looks at how well vonicog alfa (a lab-made version of a missing blood protein) works to control bleeding in children under 18 with von Willebrand disease. It follows children who are already prescribed this treatment in Japan to see how safe and effective it is in real life.
This study tests a new medicine called HMB-002 for people with von Willebrand disease. It aims to see if the drug can help control bleeding without needing regular preventive treatments.
Hear when a new Von Willebrand Disease (VWD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.